People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharmaceuticals, Hospitals and Physicians, Other Health Care, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sensorium Therapeutics, Inc. | — | Pharmaceuticals | Series B | $60.5M | $148.9M | 2022 |
| Hospitalists Now, Inc. | — | Hospitals and Physicians | Series B | $50.9M | $672.4M | 2009 |
| Lyric Pharmaceuticals Inc. | — | Pharmaceuticals | Series B | $26.8M | $910.8M | 2015 |
| ChanRx Corp. | — | Pharmaceuticals | Series B | $22.1M | $563.6M | 2011 |
| Clairity, Inc. | — | Other Health Care | Series A | $10.5M | $60.1M | 2021 |
| Ldr Holding Corp | — | Other Technology | Series A | $9.7M | $269.7M | 2012 |
| Molecular Templates, Inc. | — | Other Technology | Series A | $9.4M | $194.2M | 2009 |
| Terapio Corp | — | Other Health Care | Pre-Seed | $574K | $17.7M | 2009 |
Kevin Lalande at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin Lalande on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Casey Cunningham | 3 | 7 |
| Joe Cunningham | 2 | 5 |
| Timothy Sullivan | 1 | 16 |
| Jerel Davis | 1 | 13 |
| James Topper | 1 | 12 |
| Niall O'Donnell | 1 | 7 |
| Andreas Hildebrand | 1 | 6 |
| Arthur Brown | 1 | 5 |
| Thomas Raffin | 1 | 4 |
| Evan Melrose | 1 | 4 |
| Alexandra Glucksmann | 1 | 4 |
| Ryan Katz | 1 | 4 |
| Jason Hong | 1 | 4 |
| Robert Shepler | 1 | 4 |
| Douglas French | 1 | 4 |
| Jason Kim | 1 | 3 |
| David Southwell | 1 | 3 |
| Balkrishan Gill | 1 | 3 |
| Barry Fromberg | 1 | 2 |
| Curt Bilby | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.